[HTML][HTML] Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
[HTML][HTML] COVID-19 vaccine development: milestones, lessons and prospects
M Li, H Wang, L Tian, Z Pang, Q Yang… - Signal transduction and …, 2022 - nature.com
With the constantly mutating of SARS-CoV-2 and the emergence of Variants of Concern
(VOC), the implementation of vaccination is critically important. Existing SARS-CoV-2 …
(VOC), the implementation of vaccination is critically important. Existing SARS-CoV-2 …
[HTML][HTML] Resistance of Omicron subvariants BA. 2.75. 2, BA. 4.6, and BQ. 1.1 to neutralizing antibodies
Convergent evolution of SARS-CoV-2 Omicron BA. 2, BA. 4, and BA. 5 lineages has led to
the emergence of several new subvariants, including BA. 2.75. 2, BA. 4.6. and BQ. 1.1. The …
the emergence of several new subvariants, including BA. 2.75. 2, BA. 4.6. and BQ. 1.1. The …
[HTML][HTML] Viral persistence, reactivation, and mechanisms of long COVID
The COVID-19 global pandemic caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection has infected hundreds of millions of individuals …
coronavirus 2 (SARS-CoV-2) infection has infected hundreds of millions of individuals …
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
YM Loo, PM McTamney, RH Arends… - Science translational …, 2022 - science.org
Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines, there remains a need for more prevention and treatment options for individuals …
vaccines, there remains a need for more prevention and treatment options for individuals …
[HTML][HTML] The humoral response and antibodies against SARS-CoV-2 infection
Two and a half years into the COVID-19 pandemic, we have gained many insights into the
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …
[HTML][HTML] Neutralizing monoclonal antibodies for treatment of COVID-19
PC Taylor, AC Adams, MM Hufford… - Nature Reviews …, 2021 - nature.com
Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …
[HTML][HTML] Antibodies to combat viral infections: development strategies and progress
G Pantaleo, B Correia, C Fenwick, VS Joo… - Nature Reviews Drug …, 2022 - nature.com
Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for
viral infections owing to characteristics such as their high specificity and their ability to …
viral infections owing to characteristics such as their high specificity and their ability to …
[HTML][HTML] Tackling COVID-19 with neutralizing monoclonal antibodies
Monoclonal antibodies (mAbs) have revolutionized the treatment of several human
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …
[HTML][HTML] A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
T cell immunity is central for the control of viral infections. CoVac-1 is a peptide-based
vaccine candidate, composed of SARS-CoV-2 T cell epitopes derived from various viral …
vaccine candidate, composed of SARS-CoV-2 T cell epitopes derived from various viral …